| scholarly article | Q13442814 |
| P50 | author | Eoin R Feeney | Q58304636 |
| P2093 | author name string | Raymond T Chung | |
| P2860 | cites work | A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus | Q24307721 |
| Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 | ||
| A diverse range of gene products are effectors of the type I interferon antiviral response | Q24626018 | ||
| Chronic hepatitis C treatment outcomes in low- and middle-income countries: a systematic review and meta-analysis | Q26991791 | ||
| Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS | Q27004509 | ||
| Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro | Q27473436 | ||
| A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin | Q42967977 | ||
| Recurrent and acquired hepatitis C viral infection in liver transplant recipients | Q42983165 | ||
| High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection | Q42985356 | ||
| Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection | Q42989510 | ||
| Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial | Q42990184 | ||
| Hepatitis C in the United States | Q42992102 | ||
| Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial | Q42992205 | ||
| Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C. | Q42992556 | ||
| Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. | Q42993200 | ||
| Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. | Q42993387 | ||
| Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. | Q42998703 | ||
| Treatment of acute hepatitis C with interferon alfa-2b | Q43036093 | ||
| Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study | Q43036320 | ||
| Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation | Q43593984 | ||
| Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure | Q43804387 | ||
| Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study | Q44543175 | ||
| Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study | Q47243589 | ||
| A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on | Q85608080 | ||
| Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies | Q86309140 | ||
| Steatosis affects chronic hepatitis C progression in a genotype specific way | Q27477969 | ||
| Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome | Q27860719 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance | Q28255243 | ||
| Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence | Q29616009 | ||
| Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C | Q29619541 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| Mechanism of action of interferon and ribavirin in treatment of hepatitis C | Q29619805 | ||
| Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options | Q29620126 | ||
| Sofosbuvir for previously untreated chronic hepatitis C infection | Q29620137 | ||
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 | ||
| Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection | Q29620338 | ||
| Boceprevir for untreated chronic HCV genotype 1 infection | Q29620617 | ||
| Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
| Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource | Q33777199 | ||
| Hepatitis C: the clinical spectrum of the disease | Q33809411 | ||
| Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study | Q33956796 | ||
| Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial | Q34038836 | ||
| Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection | Q34386833 | ||
| Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial | Q34624732 | ||
| Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052 | Q34634791 | ||
| Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial | Q34649453 | ||
| Clinical consequences of hepatitis C virus infection. | Q35040078 | ||
| Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis | Q36530402 | ||
| Completion of the entire hepatitis C virus life cycle in genetically humanized mice | Q37382399 | ||
| Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients | Q37426527 | ||
| Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men. | Q37604517 | ||
| Hepatitis C virus resistance to protease inhibitors | Q37834102 | ||
| Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus | Q39376758 | ||
| New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine | Q41354692 | ||
| Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir | Q41907710 | ||
| Sofosbuvir and ribavirin in HCV genotypes 2 and 3. | Q42220605 | ||
| ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. | Q42220608 | ||
| ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis | Q42225140 | ||
| Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225540 | ||
| Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin | Q42225545 | ||
| Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial | Q42242013 | ||
| Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders | Q42242290 | ||
| Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection | Q42258200 | ||
| Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection | Q42287190 | ||
| Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C. | Q42287899 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | g3308 | |
| P577 | publication date | 2014-07-07 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Antiviral treatment of hepatitis C | |
| P478 | volume | 348 |
| Q27468939 | (4R,6S)-2-Dihydromenisdaurilide is a Butenolide that Efficiently Inhibits Hepatitis C Virus Entry |
| Q28546535 | A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients |
| Q35861251 | A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice |
| Q26798189 | A New Twist to a Chronic HCV Infection: Occult Hepatitis C |
| Q98178853 | A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment |
| Q30374768 | A Potent Anti-influenza Compound Blocks Fusion through Stabilization of the Prefusion Conformation of the Hemagglutinin Protein |
| Q47163592 | A Simple Platform for the Rapid Development of Antimicrobials. |
| Q40042032 | A Simple but Accurate Method for Evaluating Drug-Resistance in Infectious HCVcc System |
| Q38793556 | A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins |
| Q41981846 | A plant-derived dehydrorotenoid: a new inhibitor of hepatitis C virus entry |
| Q36279118 | A population-based study of chronic hepatitis C in immigrants and non-immigrants in Quebec, Canada |
| Q35164735 | A public health approach to hepatitis C control in low- and middle-income countries |
| Q26741179 | Aberrant post-translational protein modifications in the pathogenesis of alcohol-induced liver injury |
| Q37018850 | Accessibility to Oral Antiviral Therapy for Patients with Chronic Hepatitis C in the United States |
| Q38376179 | Activation of Type I and Type III Interferons in Chronic Hepatitis C. |
| Q35914175 | An observational study of the direct costs related to hospital admissions, mortality and premature death associated with liver disease in Portugal |
| Q27468952 | Assembly and release of infectious hepatitis C virus involving unusual organization of the secretory pathway |
| Q30374314 | Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design |
| Q35538674 | Challenges in managing HIV in people who use drugs |
| Q40548267 | Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens |
| Q40176558 | Clinical correlates of the "rods and rings" antinuclear antibody pattern. |
| Q35681664 | Clinical trials in noninfectious uveitis |
| Q40024158 | Conditions for eradicating hepatitis C in people who inject drugs: A fibrosis aware model of hepatitis C virus transmission. |
| Q64110985 | Control of viral infections by epigenetic-targeted therapy |
| Q35385005 | Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories |
| Q40434261 | Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity |
| Q37286311 | Detection of Natural Resistance-Associated Substitutions by Ion Semiconductor Technology in HCV1b Positive, Direct-Acting Antiviral Agents-Naïve Patients |
| Q36281158 | Determinants Involved in Hepatitis C Virus and GB Virus B Primate Host Restriction |
| Q45191773 | Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature |
| Q38885160 | Discovery of the 2-phenyl-4,5,6,7-Tetrahydro-1H-indole as a novel anti-hepatitis C virus targeting scaffold |
| Q36327141 | Early View of the Effectiveness of New Direct-Acting Antiviral (DAA) Regimens in Patients with Hepatitis C Virus (HCV) |
| Q41935139 | Effects of the Mammalian Target of Rapamycin Inhibitor Everolimus on Hepatitis C Virus Replication In Vitro and In Vivo |
| Q26771458 | Efficacy of Second Generation Direct-Acting Antiviral Agents for Treatment Naïve Hepatitis C Genotype 1: A Systematic Review and Network Meta-Analysis |
| Q28085718 | Enhancing our understanding of current therapies for hepatitis C virus (HCV) |
| Q36730021 | Escape Mutations in NS4B Render Dengue Virus Insensitive to the Antiviral Activity of the Paracetamol Metabolite AM404 |
| Q28830384 | Exploration of acetanilide derivatives of 1-(ω-phenoxyalkyl)uracils as novel inhibitors of Hepatitis C Virus replication |
| Q40225424 | Fusion expression of Occludin extracellular loops and an α-helical bundle: A new research model for tight junction |
| Q60922369 | Genetic and structural insights into broad neutralization of hepatitis C virus by human V1-69 antibodies |
| Q47800804 | Global Mortality Burden of Cirrhosis and Liver Cancer Attributable to Injection Drug Use, 1990-2016: An Age-Period-Cohort and Spatial Autocorrelation Analysis |
| Q27321791 | Hepatitis C Virus Treatment Access Among Human Immunodeficiency Virus and Hepatitis C Virus (HCV)-Coinfected People Who Inject Drugs in Guangzhou, China: Implications for HCV Treatment Expansion. |
| Q37663438 | Hepatitis C Virus in mainland China with an emphasis on genotype and subtype distribution |
| Q35604054 | Hepatitis C Virus. Strategies to Evade Antiviral Responses |
| Q37461905 | Hepatitis C virus transmission among human immunodeficiency virus-infected men who have sex with men: Modeling the effect of behavioral and treatment interventions |
| Q26768274 | Hepatitis C virus: A time for decisions. Who should be treated and when? |
| Q52661702 | Hepatitis C virus: Morphogenesis, infection and therapy. |
| Q103836761 | Hepatocellular carcinoma: old friends and new tricks |
| Q30366175 | Highlights from the 2014 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the end of the HIV pandemic. |
| Q38261733 | How will we manage acute HCV in men having sex with men in the era of all oral therapy? |
| Q47579352 | Importance and Contribution of Community, Social, and Healthcare Risk Factors for Hepatitis C Infection in Pakistan |
| Q26746563 | Interferon-Free Treatments for Chronic Hepatitis C Genotype 1 Infection |
| Q35893868 | Intrinsic Viral Factors Are the Dominant Determinants of the Hepatitis C Virus Response to Interferon Alpha Treatment in Chimeric Mice |
| Q42925798 | Kidney Transplantation in HIV-Infected Recipients: Encouraging Outcomes, but Registry Data Are No Longer Enough |
| Q40404776 | Lupus-like Immune Complex-mediated Glomerulonephritis in Patients with Hepatitis C Virus Infection Treated with Oral, Interferon-free, Direct-acting Antiviral Therapy. |
| Q37312151 | Management of hepatitis C genotype 4 in the directly acting antivirals era. |
| Q59349736 | Methanolic Extract of Inhibits the Early Viral Entry Steps of Hepatitis C Virus Infection |
| Q43059019 | Molecular classification of hepatocellular carcinoma: potential therapeutic implications |
| Q40741996 | NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection |
| Q28552134 | Natural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in China |
| Q41007229 | Naturally occurring hepatitis C virus protease inhibitors resistance-associated mutations among chronic hepatitis C genotype 1b patients with or without HIV co-infection |
| Q90086733 | New Direct-Acting Antivirals for the Treatment of Patients With Hepatitis C Virus Infection: A Systematic Review of Randomized Controlled Trials |
| Q35622533 | Novel insights into the function and dynamics of extracellular matrix in liver fibrosis |
| Q40108841 | Optimal Duration of Pegylated Interferon Plus Ribavirin Therapy for Chronic Hepatitis C Genotype 3 Patients who do not Achieve Rapid Virological Response |
| Q43593184 | Outcomes after combined liver-kidney transplant vs. kidney transplant followed by liver transplant |
| Q30376341 | Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study. |
| Q38470584 | Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals |
| Q35881575 | Personalized management of hepatocellular carcinoma based on molecular information: future prospects |
| Q41738697 | Photo-distributed lichenoid eruption secondary to direct anti-viral therapy for hepatitis C. |
| Q39603158 | Polyprotein-Driven Formation of Two Interdependent Sets of Complexes Supporting Hepatitis C Virus Genome Replication |
| Q38845669 | Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells. |
| Q35995923 | Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4. |
| Q36624431 | Prevention of hepatitis C virus infection using a broad cross-neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate |
| Q86017737 | Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? |
| Q50318635 | Project HELP: a study protocol to pilot test a shared decision-making tool about treatment options for patients with hepatitis C and chronic kidney disease |
| Q40596218 | Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population |
| Q59137629 | Quality of life of Brazilian chronic hepatitis C patients treated with interferon-free therapies |
| Q33424900 | Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). |
| Q37587202 | Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study |
| Q34515015 | Reading Out Single-Molecule Digital RNA and DNA Isothermal Amplification in Nanoliter Volumes with Unmodified Camera Phones |
| Q26752433 | Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease |
| Q35779058 | Role of genetic polymorphisms in hepatitis C virus chronic infection |
| Q38267996 | SCF ubiquitin ligase-targeted therapies. |
| Q26769709 | Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison |
| Q41285334 | Sofosbuvir and simeprevir is effective for recurrent hepatitis C in liver transplant recipients |
| Q37417839 | Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen |
| Q35912053 | Structure of Hepatitis C Virus Envelope Glycoprotein E1 Antigenic Site 314-324 in Complex with Antibody IGH526. |
| Q26768128 | Systematic Review and Network Meta-Analysis of Randomized Controlled Trials: Comparative Effectiveness and Safety of Direct-Acting Antiviral Agents for Treatment-Naive Hepatitis C Genotype 1 |
| Q41049230 | T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen |
| Q26777560 | The Seroprevalence of Hepatitis C Antibodies in Immigrants and Refugees from Intermediate and High Endemic Countries: A Systematic Review and Meta-Analysis |
| Q64916774 | The cyclophilin inhibitor CRV431 inhibits liver HBV DNA and HBsAg in transgenic mice. |
| Q64278720 | The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4 |
| Q35058574 | TnBP⁄Triton X-45 treatment of plasma for transfusion efficiently inactivates hepatitis C virus |
| Q64935822 | Tratamiento personalizado del carcinoma hepatocelular basado en información molecular: perspectivas futuras. |
| Q38557983 | Treatment of chronic HCV genotype 1 coinfection |
| Q40143151 | Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience |
| Q26777048 | Update on hepatitis B and C virus diagnosis |
Search more.